Table 3.
Summary of HMT inhibitors.
| Inhibitor | Target point | Disease model |
|---|---|---|
| BIX01294 | G9a | IR-AKI, cisplatin-AKI, UUO-RF |
| UNC0638 | G9a | RCC |
| CM272 | G9a | UUO-RF |
| 3-DZNeP | EZH2 | IR-AKI, cisplatin-AKI, sepsis-AKI, UUO-RF, TGF-β1-RF, hyperuricemia nephropathy, SLE |
| ZLD1039 | EZH2 | Cisplatin-AKI |
| BAY2416964 | AhR, EZH2 | Cisplatin-AKI |
| EED226 | PRC2, EZH2 | Cisplatin-AKI |
| GSK-126 | EZH2 | UUO-RF, RCC, PKD, hyperuricemia nephropathy |
| MM102 | MLL1/WDR5 complex | IR-AKI, UUO-RF |
| EPZ004777 | DOT1L | IR-AKI |
| AZ505 | SMYD2 | IR-AKI, UUO-RF, PKD |
| Chaetocin | Suv39h1, Suv39h2 | UUO-RF, high glucose-DN |
| ORY1001 | LSD1 | UUO-RF |
| Sinefungin | SET7/9 | UUO-RF |
| MA-35 | SET7/9 | UUO-RF |
| AMI-1 | PRMT1 | UUO-RF |
| EPZ5676 | DOT1L | UUO-RF |
Abbreviations: HMT, histone methylation; KDs, kidney diseases; AKI, acute kidney injury; IR, ischemia-reperfusion; UUO, unilateral ureteral obstruction; RF, renal fibrosis; DN, diabetic nephropathy; RCC, renal cell carcinoma; SLE, systemic lupus erythematosus; TGF-β1, transforming growth factor beta 1; EZH2, enhancer of zeste homologs 2; AhR, aryl hydrocarbon receptor; Suv39h1, suppressor of variegation 3-9 homolog 1; JMJD3, Jumonji domain containing protein 3; Suv39h2, suppressor of variegation 3-9 homolog 2; G9a, euchromatic histone lysine methyltransferase 2; MLL1, myeloid/lymphoid or mixed-lineage leukemia 1; SET7/9, set domain-containing proteins 7/9; Dot1L, disruptor of telomeric silencing 1-like; SMYD2, SET and MYND domain containing protein 2; PRMT1, protein arginine methyltransferase 1; PRC2, polycomb repressive complex 2.